A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma
复制标题
DOI：
10.1093/annonc/mdp193
复制
发表时间：
2009-11-01
影响因子：
50.5
通讯作者：
Kaye, S. B.
中科院分区：
文献类型：
--
作者：
Ang, J. E.;Shah, R. N.;Kaye, S. B.
患者和方法：共有52名晚期或复发性子宫内膜癌和癌肉瘤的妇女接受4个周期的卡铂曲线下面积（AUC） 5和阿霉素（50 mg/m(2)）治疗，在卡铂AUC5和紫杉醇（175 mg/m(2)） 4个周期之前或之后，每个周期间隔21天给药。结果：37例患者（71.2%）完成了所有计划治疗。排除6例因非药物相关原因未完成治疗的患者，80.4%的患者完成了所有计划治疗。371个治疗周期，303个（81.7%）按时完成。常见毒性标准3/4级血液学毒性作用，特别是中性粒细胞减少和血小板减少，是治疗延误和剂量减少的主要原因。3级神经毒性发生率低，无心脏毒性。可评估疾病的子宫内膜和癌肉瘤患者的总有效率分别为82.1%和66.7%。在21个月的中位随访中，子宫内膜腺癌和癌肉瘤的中位无进展生存期分别为15.3个月和12.0个月。结论：该方案耐受性良好，疗效令人鼓舞。
Patients and methods: A total of 52 women with advanced or recurrent endometrial cancer and carcinosarcoma were treated with four cycles of carboplatin area under the curve (AUC) 5 and doxorubicin (50 mg/m(2)) for four cycles before or after four cycles of carboplatin AUC5 and paclitaxel (175 mg/m(2)) with each cycle administered at 21-day intervals.Results: Thirty-seven patients (71.2%) completed all planned treatment. Excluding six patients who did not complete treatment for non-drug-related causes, 80.4% completed all planned treatment. Three hundred and seventy-one treatment cycles were administered and 303 (81.7%) occurred on time. Common Toxicity Criteria grade 3/4 haematological toxic effects, particularly neutropenia and thrombocytopenia, were the predominant cause of treatment delays and dose reductions. A low incidence of grade 3 neurotoxicity and no cardiac toxicity were observed. The overall response rates for patients with evaluable disease were 82.1% and 66.7% for endometrial and carcinosarcoma, respectively. At a median follow-up of 21 months, the median progression-free survival for the endometrial adenocarcinoma and carcinosarcoma cohorts were 15.3 and 12.0 months, respectively.Conclusion: This regimen is generally well tolerated with encouraging efficacy.